Alpha Biopharma

Alpha Biopharma is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Shanghai, China, with an additional office in Beijing. The company focuses on the clinical development and commercialization of global innovative drugs across oncology and immunotherapy, spanning medical affairs, clinical operations, regulatory affairs and commercialization. Its lead product is Zorifertinib (formerly AZD-3759, marketed as Zorifer), a next-generation EGFR TKI designed for EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which received NMPA approval in November 2024 as the first EGFR-TKI indicated for lung cancer with brain metastases. Alpha Biopharma also partners with Wugen Inc. on universal off-the-shelf memory NK and CAR-T cell therapies. The company raised a Series A led by Qiming Venture Partners. Alpha Biopharma publishes a corporate marketing website only and operates no public API, developer portal, or software platform.

Alpha Biopharma is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Pharmaceuticals, Oncology, and Immunotherapy.

Alpha Biopharma’s developer surface includes engineering blog and 16 more developer resources.

🌐 Visit website 📡 Source on GitHub

8.1/100 minimal ▬ flat Agent 4/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiopharmaceuticalPharmaceuticalsOncologyImmunotherapyClinical DevelopmentLife SciencesChina

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 8.1/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.4 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 4/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 4 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/alphabiopharma: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 2

MCP servers, agent skills, and machine-readable catalogs

WellKnown

WellKnown

LLMsTxt

LLMsTxt

Build 1

SDKs, sample code, and the tooling you integrate with

Packages

Packages

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Company 6

The organization behind the API

Website

About

Blog

Press

Careers

Investors

Other 6

Properties that don't map to a standard resource type

Pipeline

Publications

Research

Products

TherapeuticAreas

CorporateSocialResponsibility

CorporateSocialResponsibility

Source (apis.yml)

aid: alphabiopharma
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/alphabiopharma.png
name: Alpha Biopharma
description: Alpha Biopharma is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Shanghai,
  China, with an additional office in Beijing. The company focuses on the clinical development and commercialization of global
  innovative drugs across oncology and immunotherapy, spanning medical affairs, clinical operations, regulatory affairs and
  commercialization. Its lead product is Zorifertinib (formerly AZD-3759, marketed as Zorifer), a next-generation EGFR TKI
  designed for EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which received NMPA
  approval in November 2024 as the first EGFR-TKI indicated for lung cancer with brain metastases. Alpha Biopharma also partners
  with Wugen Inc. on universal off-the-shelf memory NK and CAR-T cell therapies. The company raised a Series A led by Qiming
  Venture Partners. Alpha Biopharma publishes a corporate marketing website only and operates no public API, developer portal,
  or software platform.
url: https://raw.githubusercontent.com/api-evangelist/alphabiopharma/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- qiming
x-tier: stub
x-tier-reason: no-public-api-surface
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biopharmaceutical
- Pharmaceuticals
- Oncology
- Immunotherapy
- Clinical Development
- Life Sciences
- China
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/alphabiopharma-domain-security.yml
- type: Website
  url: https://www.alphabiopharma.com/en/
- type: About
  url: https://www.alphabiopharma.com/en/company/1.html
- type: Blog
  url: https://www.alphabiopharma.com/en/news/15.html
- type: Press
  url: https://www.alphabiopharma.com/en/news/36.html
- type: Pipeline
  url: https://www.alphabiopharma.com/en/productline/30.html
- type: Contact
  url: https://www.alphabiopharma.com/en/contact/23.html
- type: Careers
  url: https://www.alphabiopharma.com/en/vocation/20.html
- type: Investors
  url: https://www.alphabiopharma.com/en/investment/27.html
- type: Publications
  url: https://www.alphabiopharma.com/en/innovation/38.html
- type: Research
  url: https://www.alphabiopharma.com/en/development/31.html
- type: Products
  url: https://www.alphabiopharma.com/en/medicine1/32.html
- type: TherapeuticAreas
  url: https://www.alphabiopharma.com/en/ta/7.html
- type: CorporateSocialResponsibility
  url: https://www.alphabiopharma.com/en/society/29.html
- type: WellKnown
  url: well-known/alphabiopharma-well-known.yml
- type: Packages
  url: packages/alphabiopharma-packages.yml
- type: LLMsTxt
  url: llms/alphabiopharma-llms.txt
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 1
  pass: local-v1